Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 48

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 48
---
109,238 shares of common stock that are held by EcoR1 Capital, LLC (“EcoR1”). EcoR1 is the general partner of EcoR1 Capital Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share dispositive voting power over the shares held by the EcoR1 Capital Funds. Mr. Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. The address for EcoR1 Capital LLC, the EcoR1 Capital Funds and Oleg Nodelman is 357 Tehama Street #3, San Francisco, CA.

(5) Consists of (i) 2,535,488 shares of common stock held by Acuta Capital Fund, L.P. (“Acuta Capital”) and (ii) 874,914 shares held by Acuta Opportunity Fund, L.P. (“Acuta Opportunity Fund”). Acuta Capital Partners, LLC (“Acuta Partners”) is a general partner of each of Acuta Capital and Acuta Opportunity Fund. According to the Schedule 13D/A filed with the SEC on January 24, 2025, Acuta Partners has shared voting power and shared dispositive power with regard to 1,849,402 shares of common stock. Dr. Dalal, a director of the Company, is the Chief Investment Officer and Managing Member of Acuta Partners. Dr. Dalal has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and Dr. Dalal disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein. The principal business address of each of the entities and individuals above is c/o Acuta Capital Partners, LLC, 255 Shoreline Drive, Suite 515, Redwood City, California 94065.

<div align='center'>30</div>

(6) Based solely on a Schedule 13G filed with the SEC on March 11, 2025, consists of (i) 817,939 shares of common stock held of record by Ally Bridge MedAlpha Master Fund LP; (ii) 26,666 shares of common stock held of record by ABG Innovation-SO Limited; and (iii) 2,070,000 shares of common stock purchased in the PIPE Financing by ABG V-SIV